Posts tagged Squamous cell carcinoma
Management of Advanced Disease in NSCLC
Management of Advanced Disease in NSCLC

Lung cancer remains the leading cause of cancer death world-wide. This is in part due patients presenting late with disseminated disease and despite recent advances, a limited therapeutic landscape... Despite these advances there remains a significant unmet clinical need with much research needed to elucidate the optimal treatment paradigm to improve response rates, mortality and quality of life for patients with advanced NSCLC. READ ARTICLE

Encyclopedia of Respiratory Medicine (Second Edition) DOI:10.1016/B978-0-08-102723-3.00265-1

Authors: Alice Davies, Martin Forster

Read More
EditorialKirk SmithAdenocarcinoma, Advanced lung cancer, Atezolizumab, Carboplatin, Chemotherapy, Cisplatin, Doxcetaxal, Driver mutations, Gemcitabine, Immunotherapy, Lung cancer, Metastatic lung cancer, Nivolumab, Non small cell, Palliative care, PD1, PDL1, Pembrolizumab, Small cell, Smoking, Smoking cessation, Squamous cell carcinoma, Targeted therapies, Treatment, Vinorelbine
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor

Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) treated with ALK tyrosine kinase inhibitor (TKI) eventually acquires resistance to the treatment. However, our current knowledge regarding the resistance mechanisms is based on non-synonymous mutation and amplification in ALK, with the reasons still unknown for nearly half of all such cases. Other than genomic alteration as a resistance mechanism, up to 10% of NSCLC with activating epithelial growth factor receptor (EGFR) mutation showed resistance to EGFR TKI through histologic transformation. Although limited in number, there are cases showing transformed samples retaining the initial genomic alteration, which support lineage transition as a novel resistance mechanism. In this report, we described the first case of squamous cell carcinoma (SCC) transformation from adenocarcinoma (ADC) in NSCLC with ALK rearrangement after treatment with ALK TKI. READ ARTICLE

Lung Cancer DOI:10.1016/j.lungcan.2018.11.027

Authors: Sehhoon Park, Joungho Han, Jong-Mu Sun

Read More
Case StudyKirk SmithNon-small cell lung cancer (NSCLC), Adenocarcinoma, Squamous cell carcinoma, Anaplastic lymphoma kinase (ALK)